• Jacqueline S Garcia and Richard M Stone.
• Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Dana 2058, Boston, MA 02215-5450, USA. Electronic address: jacqueline_garcia@dfci.harvard.edu.
• Hematol. Oncol. Clin. North Am. 2017 Aug 1; 31 (4): 663-680.

AbstractFLT3 mutations, generally associated with a poor prognosis, are found in approximately one-third of patients with acute myeloid leukemia (AML) and represent an attractive therapeutic target. FLT3 inhibitors undergoing clinical evaluation include first-generation relatively non-specific small molecules and second-generation compounds with higher potency and selectivity against mutant FLT3. Recently presented results from a prospective randomized clinical trial will likely lead to a change in the standard of care for younger patients with FLT3-mutated AML: addition of the multi-targeted FLT3 inhibitor midostaurin to standard induction and consolidation chemotherapy. Thus, personalized therapies for this subset of AML will soon be possible.Copyright © 2017 Elsevier Inc. All rights reserved.

31 keywords...

hide…